Literature DB >> 25522175

Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score.

Juan P de-Torres1, David O Wilson, Pablo Sanchez-Salcedo, Joel L Weissfeld, Juan Berto, Arantzazu Campo, Ana B Alcaide, Marta García-Granero, Bartolome R Celli, Javier J Zulueta.   

Abstract

RATIONALE: Patients with chronic obstructive pulmonary disease (COPD) are at high risk for lung cancer (LC) and represent a potential target to improve the diagnostic yield of screening programs.
OBJECTIVES: To develop a predictive score for LC risk for patients with COPD.
METHODS: The Pamplona International Early Lung Cancer Detection Program (P-IELCAP) and the Pittsburgh Lung Screening Study (PLuSS) databases were analyzed. Only patients with COPD on spirometry were included. By logistic regression we determined which factors were independently associated with LC in PLuSS and developed a COPD LC screening score (COPD-LUCSS) to be validated in P-IELCAP.
MEASUREMENTS AND MAIN RESULTS: By regression analysis, age greater than 60, body mass index less than 25 kg/m(2), pack-years history greater than 60, and emphysema presence were independently associated with LC diagnosis and integrated into the COPD-LUCSS, which ranges from 0 to 10 points. Two COPD-LUCSS risk categories were proposed: low risk (scores 0-6) and high risk (scores 7-10). In comparison with low-risk patients, in both cohorts LC risk increased 3.5-fold in the high-risk category.
CONCLUSIONS: The COPD-LUCSS is a good predictor of LC risk in patients with COPD participating in LC screening programs. Validation in two different populations adds strength to the findings.

Entities:  

Keywords:  COPD; lung cancer; screening

Mesh:

Year:  2015        PMID: 25522175      PMCID: PMC4351574          DOI: 10.1164/rccm.201407-1210OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  35 in total

1.  Diagnosing COPD and targeted lung cancer screening.

Authors:  Robert P Young; Raewyn J Hopkins
Journal:  Eur Respir J       Date:  2012-10       Impact factor: 16.671

2.  CT screening in COPD: impact on lung cancer mortality: de Torres JP, Casanova C, Marin JM et al. Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study. Respir med 2013; 107: 702-707.

Authors:  R P Young; R J Hopkins
Journal:  Respir Med       Date:  2014-02-12       Impact factor: 3.415

3.  Airways obstruction and the risk for lung cancer.

Authors:  M S Tockman; N R Anthonisen; E C Wright; M G Donithan
Journal:  Ann Intern Med       Date:  1987-04       Impact factor: 25.391

Review 4.  Malignancy after renal transplantation: the role of immunosuppression.

Authors:  Inés Rama; Josep M Grinyó
Journal:  Nat Rev Nephrol       Date:  2010-09       Impact factor: 28.314

5.  Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

Review 6.  Mortality in COPD: Role of comorbidities.

Authors:  D D Sin; N R Anthonisen; J B Soriano; A G Agusti
Journal:  Eur Respir J       Date:  2006-12       Impact factor: 16.671

7.  A gene-based risk score for lung cancer susceptibility in smokers and ex-smokers.

Authors:  R P Young; R J Hopkins; B A Hay; M J Epton; G D Mills; P N Black; H D Gardner; R Sullivan; G D Gamble
Journal:  Postgrad Med J       Date:  2009-10       Impact factor: 2.401

8.  Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest.

Authors:  Juan P de Torres; Gorka Bastarrika; Juan P Wisnivesky; Ana B Alcaide; Arantza Campo; Luis M Seijo; Jesús C Pueyo; Alberto Villanueva; María D Lozano; Usua Montes; Luis Montuenga; Javier J Zulueta
Journal:  Chest       Date:  2007-12       Impact factor: 9.410

Review 9.  Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Frank C Detterbeck; Peter J Mazzone; David P Naidich; Peter B Bach
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

10.  Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study.

Authors:  D M Skillrud; K P Offord; R D Miller
Journal:  Ann Intern Med       Date:  1986-10       Impact factor: 25.391

View more
  40 in total

1.  IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer.

Authors:  Ran You; Francesco J DeMayo; Jian Liu; Sung-Nam Cho; Bryan M Burt; Chad J Creighton; Roberto F Casal; Donald R Lazarus; Wen Lu; Hui-Ying Tung; Xiaoyi Yuan; Andrea Hill-McAlester; Myunghoo Kim; Sarah Perusich; Loraine Cornwell; Daniel Rosen; Li-Zhen Song; Silke Paust; Gretchen Diehl; David Corry; Farrah Kheradmand
Journal:  Cancer Immunol Res       Date:  2018-04-13       Impact factor: 11.151

2.  Recommendations from the European Society of Thoracic Surgeons (ESTS) regarding computed tomography screening for lung cancer in Europe.

Authors:  Jesper Holst Pedersen; Witold Rzyman; Giulia Veronesi; Thomas A D'Amico; Paul Van Schil; Laureano Molins; Gilbert Massard; Gaetano Rocco
Journal:  Eur J Cardiothorac Surg       Date:  2017-03-01       Impact factor: 4.191

3.  Update in Lung Cancer 2015.

Authors:  Avrum Spira; Balazs Halmos; Charles A Powell
Journal:  Am J Respir Crit Care Med       Date:  2016-09-15       Impact factor: 21.405

Review 4.  The 2017 Update to the COPD Foundation COPD Pocket Consultant Guide.

Authors:  Barbara Bp Yawn; Byron Thomashaw; David M Mannino; MeiLan K Han; Ravi Kalhan; Stephen Rennard; Scott Cerrata; James D Crapo; Robert Wise
Journal:  Chronic Obstr Pulm Dis       Date:  2017-07-15

5.  Lung cancer screening: how do we make it better?

Authors:  David O Wilson; Juan Pablo de Torres
Journal:  Quant Imaging Med Surg       Date:  2020-02

6.  Tumor necrosis factor links chronic obstructive pulmonary disease and K-ras mutant lung cancer through induction of an immunosuppressive pro-tumor microenvironment.

Authors:  Lei Gong; Mauricio da Silva Caetano; Amber M Cumpian; Soudabeh Daliri; Alejandra Garza Flores; Seon Hee Chang; Cesar E Ochoa; Christopher M Evans; Zhentao Yu; Seyed Javad Moghaddam
Journal:  Oncoimmunology       Date:  2016-09-02       Impact factor: 8.110

Review 7.  Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.

Authors:  Prescott G Woodruff; Alvar Agusti; Nicolas Roche; Dave Singh; Fernando J Martinez
Journal:  Lancet       Date:  2015-05-02       Impact factor: 79.321

8.  IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.

Authors:  Mauricio S Caetano; Huiyuan Zhang; Amber M Cumpian; Lei Gong; Nese Unver; Edwin J Ostrin; Soudabeh Daliri; Seon Hee Chang; Cesar E Ochoa; Samir Hanash; Carmen Behrens; Ignacio I Wistuba; Cinthya Sternberg; Humam Kadara; Carlos Gil Ferreira; Stephanie S Watowich; Seyed Javad Moghaddam
Journal:  Cancer Res       Date:  2016-04-01       Impact factor: 12.701

Review 9.  Lung cancer screening in patients with chronic obstructive pulmonary disease.

Authors:  Jessica Gonzalez; Marta Marín; Pablo Sánchez-Salcedo; Javier J Zulueta
Journal:  Ann Transl Med       Date:  2016-04

10.  IL22 Promotes Kras-Mutant Lung Cancer by Induction of a Protumor Immune Response and Protection of Stemness Properties.

Authors:  Nasim Khosravi; Mauricio S Caetano; Amber M Cumpian; Nese Unver; Cynthia De la Garza Ramos; Oscar Noble; Soudabeh Daliri; Belinda J Hernandez; Berenice A Gutierrez; Scott E Evans; Samir Hanash; Andrei M Alekseev; Yi Yang; Seon Hee Chang; Roza Nurieva; Humam Kadara; Jichao Chen; Edwin J Ostrin; Seyed Javad Moghaddam
Journal:  Cancer Immunol Res       Date:  2018-05-15       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.